Biotron Limited Stock Net Income

BITRF Stock  USD 0  0.00  0.00%   
As of the 10th of February, Biotron shows the Standard Deviation of 209.19, risk adjusted performance of 0.0959, and Mean Deviation of 50.58. Biotron Limited technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Biotron Limited variance and skewness to decide if Biotron Limited is priced correctly, providing market reflects its regular price of 0.003 per share. As Biotron Limited appears to be a penny stock we also recommend to validate its information ratio numbers.
Biotron's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biotron's valuation are provided below:
Biotron Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
It's important to distinguish between Biotron's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biotron should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biotron's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Biotron 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biotron's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biotron.
0.00
11/12/2025
No Change 0.00  0.0 
In 2 months and 31 days
02/10/2026
0.00
If you would invest  0.00  in Biotron on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Biotron Limited or generate 0.0% return on investment in Biotron over 90 days. Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat var... More

Biotron Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biotron's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biotron Limited upside and downside potential and time the market with a certain degree of confidence.

Biotron Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotron's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biotron's standard deviation. In reality, there are many statistical measures that can use Biotron historical prices to predict the future Biotron's volatility.
Hype
Prediction
LowEstimatedHigh
0.00050.15
Details
Intrinsic
Valuation
LowRealHigh
0.00050.15
Details

Biotron February 10, 2026 Technical Indicators

Biotron Limited Backtested Returns

Biotron is out of control given 3 months investment horizon. Biotron Limited secures Sharpe Ratio (or Efficiency) of 0.099, which signifies that the company had a 0.099 % return per unit of risk over the last 3 months. We were able to interpolate data for sixteen different technical indicators, which can help you to evaluate if expected returns of 12.72% are justified by taking the suggested risk. Use Biotron Risk Adjusted Performance of 0.0959, mean deviation of 50.58, and Standard Deviation of 209.19 to evaluate company specific risk that cannot be diversified away. Biotron holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.9, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Biotron are expected to decrease by larger amounts. On the other hand, during market turmoil, Biotron is expected to outperform it. Use Biotron variance, skewness, as well as the relationship between the Skewness and day typical price , to analyze future returns on Biotron.

Auto-correlation

    
  0.71  

Good predictability

Biotron Limited has good predictability. Overlapping area represents the amount of predictability between Biotron time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biotron Limited price movement. The serial correlation of 0.71 indicates that around 71.0% of current Biotron price fluctuation can be explain by its past prices.
Correlation Coefficient0.71
Spearman Rank Test-0.12
Residual Average0.0
Price Variance0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Biotron Limited reported net income of (2.78 Million). This is 100.81% lower than that of the Healthcare sector and 103.97% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.49% higher than that of the company.

Biotron Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotron's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biotron could also be used in its relative valuation, which is a method of valuing Biotron by comparing valuation metrics of similar companies.
Biotron is currently under evaluation in net income category among its peers.

Biotron Fundamentals

About Biotron Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Biotron Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotron Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Biotron Pink Sheet

Biotron financial ratios help investors to determine whether Biotron Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotron with respect to the benefits of owning Biotron security.